General pharmaceutical principles for handling lyophilised peptides apply to ipamorelin. However, no independently published, peer-reviewed stability studies specific to this compound have been identified in the scientific literature reviewed for this article. This means that the specific storage duration figures circulating commercially reflect manufacturer or vendor convention rather than confirmed, independent research. This article carefully maintains that distinction throughout.
How to store Ipamorelin
As a matter of general pharmaceutical peptide science, ipamorelin, like other peptides, is typically supplied as a lyophilised powder. This dry state is generally more chemically stable over time than the same peptide already dissolved in liquid. Standard practice for lyophilised peptides broadly, consistent across pharmaceutical and laboratory guidelines, calls for the storage of unopened powder in a cool, dry, dark environment, protected from light and moisture. Refrigerated storage, around -20°C, is commonly recommended for maximising the shelf-life of unreconstituted powder over long periods.
Once reconstituted into a liquid form, the general pharmaceutical convention, derived from well-researched comparable products such as multi-dose insulin, dictates that the resulting solution should be refrigerated, commonly between 2–8°C, rather than stored at room temperature. Dissolved peptides are understood to be more susceptible to degradation from heat, light, and time than their lyophilised counterparts.
Regarding the freezing of reconstituted solution specifically, general laboratory handling guidelines for peptides commonly advise against repeated freeze-thaw cycling. The physical process of freezing and thawing a liquid can potentially disrupt the peptide's structure through ice crystal formation and mechanical stress. This is a widely applicable caution for peptides handled as liquids – not a discovery from a dedicated ipamorelin freeze-thaw study.
It is worth being direct that these storage practices reflect general, well-established principles applied consistently throughout the field of peptide handling, rather than discoveries from an independently published study measuring the specific degradation rate of ipamorelin under controlled conditions.
Regarding the separate question about taking ipamorelin on an empty stomach, this pertains to timing, not storage. As discussed in an earlier article in this series, the general reasoning is that elevated blood glucose and insulin after eating are known in general endocrinology to suppress growth hormone release. This is the probable basis for the common suggestion to fast, though it has not been directly tested as a dedicated study of fasted versus fed for ipamorelin itself.
How long does Ipamorelin last in the fridge?
This is an area requiring the most caution, as here the gap between commercial claims and independently verified science is widest. Commercial and laboratory sources commonly describe reconstituted ipamorelin as remaining stable under refrigeration for periods often cited somewhere between two and four weeks. Different sources offer slightly different specific numbers within this general range. These numbers should be understood as manufacturer or seller guidelines and general industry convention—not as findings from independently conducted, peer-reviewed stability testing. No such published study measuring the actual rate of chemical degradation of ipamorelin over time after reconstitution has been identified in the literature reviewed for this article.
This is an important distinction to remember. A vendor stating a stability number on a product page is not the same as a controlled analytical chemistry study measuring how much intact, active peptide remains at specific time points after reconstitution. This latter type of independent verification does not appear to exist in the published record specifically for ipamorelin yet.
Regarding how long unopened, unconstituted ipamorelin powder remains viable, similarly no independently published stability study has been identified. General peptide science would suggest, however, that the dry powder form remains stable for considerably longer than a reconstituted solution, in accordance with the general rule described above.
Regarding how long ipamorelin can tolerate being unrefrigerated, whether as a powder or after reconstitution, no dedicated stability data exists in the peer-reviewed literature reviewed here. Any specific number of hours or days offered elsewhere should be treated as an informal guideline, not confirmed science.
It is worth separately and clearly addressing another commonly confused question. How long does ipamorelin remain active in the body after a dose? This is a distinct pharmacokinetic question with a real, readily available answer. Human studies have shown ipamorelin to have a short terminal half-life of about two hours. Its growth hormone-stimulating effect peaks around 40 minutes after administration, and returns to baseline within approximately six hours [1].
This describes how quickly a compound is cleared from the bloodstream after use. This is a completely separate matter from how long a reconstituted vial remains chemically stable for future use.
Limitations of current evidence
The general storage principles described in this article are well-established and broadly applicable to lyophilised peptides as a category. This includes why peptides are supplied freeze-dried, why refrigeration is recommended for reconstituted solutions, and why repeated freeze-thaw cycling is generally discouraged.
What remains truly absent from the reviewed literature is dedicated, independently published stability research measuring the specific degradation rate of ipamorelin, whether in powder form or reconstituted. This means that the two-to-four-week figures commonly cited commercially should be understood as manufacturer or vendor claims, rather than verified, independent scientific findings.
Disclaimer
Ipamorelin is not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body for any human use, and no independently published, peer-reviewed stability or durability study specific to the compound has been identified for this article. It is not manufactured or sold under the quality and safety oversight that applies to approved pharmaceuticals. The storage information provided herein reflects general, well-established principles for pharmaceutical handling of peptides and is intended for educational purposes only. It does not constitute manufacturer-verified stability data, nor is it medical or laboratory advice. This article is provided for general educational and informational purposes only, reflects the state of the published scientific literature at the time of writing, and nothing herein should be interpreted as a recommendation for the use, procurement, or administration of ipamorelin.
References
Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402